RxDoctor Payments Data

Ramashilpa Sudireddy, MD

Family Medicine · Sugar Land, TXNPI 1700084670

Payments from drug & device makers

$1,461in general payments, 2019–2025

Across 84 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$615
  • Lilly USA, LLC$138
  • Novo Nordisk$116
  • GSK$97
  • Dexcom, Inc.$92
  • Astellas Pharma US Inc$63
  • plus $340 from 13 others

What the payments were for

  • Food & beverage$1,461100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,461 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$55,011
Medicare patients
129
Services billed
1,098

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin66$71,006
OzempicSemaglutide59$59,791
EliquisApixaban44$45,332
TrulicityDulaglutide36$41,411
MyrbetriqMirabegron49$41,317
MounjaroTirzepatide34$36,241
JanuviaSitagliptin Phosphate21$30,263
ProliaDenosumab18$29,866
Trijardy XrEmpaglifloz/Linaglip/Metformin24$18,523
XareltoRivaroxaban16$15,056
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$11,853
Tresiba Flextouch U-200Insulin Degludec18$9,860
Rosuvastatin Calcium426$9,641
FarxigaDapagliflozin Propanediol11$9,496
Breo ElliptaFluticasone/Vilanterol17$7,093

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Trijardy Xr$22$89,52890 claims
Lilly USA, LLCTrulicity, Mounjaro$138$77,65370 claims
Novo NordiskOzempic$116$59,79159 claims
Astellas Pharma US IncMyrbetriq$63$41,31749 claims
MerckJanuvia$52$30,26321 claims
AmgenProlia$14$29,86618 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$97$24,91161 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →